ABSTRACT
1-(Benzothiazol-2-yl)-1-(4-chlorophenyl)ethanol (1) was identified as a positive allosteric modulator (PAM) of the CaSR in a functional cell-based assay. This compound belongs to a class of compounds that is structurally distinct from other known positive allosteric modulators, for example, the phenylalkylamines cinacalcet, a modified analog (13) potently suppressed parathyroid hormone (PTH) release in rats, consistent with its profile as a PAM of CaSRs.
Subject(s)
Benzothiazoles/chemistry , Benzyl Alcohols/chemistry , Phenylethyl Alcohol/chemistry , Receptors, Calcium-Sensing/chemistry , Allosteric Regulation , Animals , Benzothiazoles/chemical synthesis , Benzothiazoles/pharmacology , Benzyl Alcohols/pharmacology , Cinacalcet , Drug Evaluation, Preclinical , Humans , Microsomes, Liver/metabolism , Naphthalenes/chemistry , Parathyroid Hormone/metabolism , Phenylethyl Alcohol/chemical synthesis , Phenylethyl Alcohol/pharmacology , Rats , Receptors, Calcium-Sensing/metabolism , Structure-Activity RelationshipABSTRACT
A series of novel isochromanone based urotensin II receptor agonists have been synthesized and evaluated for their activity using a functional cell based assay (R-SAT). Several potent and efficacious derivatives were identified, with 3-(3,4-dichlorophenyl)-6,7-dimethyl-3-(2-dimethylaminoethyl)isochroman-1-one being the most potent compound showing an EC50-value of 51 nM, thereby being the most potent compound so far within the isochromanone series. In addition, two other heterocyclic systems (isochromanes and tetrahydroisoquinolinones) were investigated and these derivatives were found to be both potent and efficacious. The activity of the isochromane derivatives implies that the carbonyl group of the isochromanone is not necessary for activity. Furthermore it was found that the geometry of the heterocycles was more important for receptor interaction than the composition of the heteroatoms present.
Subject(s)
Chromans/chemistry , Receptors, G-Protein-Coupled/agonists , Benzamides/chemical synthesis , Benzamides/chemistry , Chromans/chemical synthesis , Chromans/pharmacology , Humans , Receptors, G-Protein-Coupled/metabolism , Structure-Activity RelationshipABSTRACT
A class of small molecules displaying comparable activities with peptide ligands BAM22 and corticostatin-14 at both the human and rhesus monkey MrgX1 and MrgX2 receptors, respectively, was discovered. A comparative study to compare solid-phase and solution-phase chemistries for the efficient synthesis of the active class, tetracyclic benzimidazoles, was undertaken. The solid-phase chemistry was found to be superior both for the synthesis of analogs and for the synthesis of gram quantities.
Subject(s)
Chemistry, Pharmaceutical/methods , Nerve Tissue Proteins/agonists , Nerve Tissue Proteins/chemistry , Receptors, G-Protein-Coupled/agonists , Receptors, G-Protein-Coupled/chemistry , Receptors, Neuropeptide/agonists , Receptors, Neuropeptide/chemistry , Animals , Benzimidazoles/chemistry , Cattle , Combinatorial Chemistry Techniques , Drug Design , Humans , Intercellular Signaling Peptides and Proteins , Ligands , Macaca mulatta , Models, Chemical , Peptides/chemistry , Structure-Activity RelationshipABSTRACT
A series of analogs of the non-peptidic urotensin II receptor agonist N-[1-(4-chlorophenyl)-3-(dimethylamino)propyl]-4-phenylbenzamide (FL104) has been synthesized and evaluated pharmacologically. The enantiomers of the two most potent racemic analogues were obtained from the corresponding diastereomeric mandelic amides. In agreement with previously observed SAR, most of the agonist potency resided in the (S) enantiomers. The most potent UII receptor agonist in the new series was (S)-N-[3-dimethylamino-1-(2-naphthyl)propyl]-4-(4-chlorophenyl)benzamide (EC(50)=23 nM at the urotensin II receptor).
Subject(s)
Benzamides/chemistry , Benzamides/pharmacology , Receptors, G-Protein-Coupled/agonists , Receptors, G-Protein-Coupled/metabolism , Animals , Benzamides/chemical synthesis , Crystallography, X-Ray , Humans , Mice , Models, Molecular , Molecular Structure , NIH 3T3 Cells , Structure-Activity RelationshipABSTRACT
Steroidogenic factor SF-1, a constitutively active nuclear hormone receptor, is essential to the development of adrenal and gonadal glands and acts as a shaping factor of sexual determination and differentiation. Its effects are exerted primarily through the control of the synthesis of steroid hormones. The functional cell-based assay Receptor Selection and Amplification Technology (R-SAT) was used to identify potent and selective SF-1 inverse agonists through the screening of a chemical library of drug-like small-molecule entities. Among them, 4-(heptyloxy)phenol (AC-45594), a prototype inverse agonist lead, was used to show that SF-1 constitutive activity can be pharmacologically modulated by a synthetic ligand. In a physiological system of endocrine function, the expression of several reported SF-1 target genes, including SF-1 itself, was inhibited by treatment with AC-45594 and analogs. Thus, pharmacological modulation of SF-1 is critical to its function as an endocrine master regulator and has potentially important consequences to diseases in which SF-1 activity is critical.
Subject(s)
Cholesterol Side-Chain Cleavage Enzyme/genetics , Drug Evaluation, Preclinical/methods , Phenols/pharmacology , Steroidogenic Factor 1/agonists , Steroidogenic Factor 1/chemical synthesis , Adrenal Gland Neoplasms/pathology , Animals , Carcinoma/pathology , Cell Proliferation/drug effects , Cholesterol Side-Chain Cleavage Enzyme/metabolism , Cyclic AMP/pharmacology , Genes, Reporter , Humans , Inhibitory Concentration 50 , Ligands , Luciferases/metabolism , Mice , Mutation , NIH 3T3 Cells , RNA, Messenger/metabolism , Steroidogenic Factor 1/chemistry , Steroidogenic Factor 1/genetics , Transcription, Genetic , Transcriptional Activation , Transfection , Tumor Cells, CulturedABSTRACT
A 30-membered library of amides based on the potent urotensin II (UII) receptor agonist FL104, has been synthesized from ten different carboxylic acids and three amines. A synthetic protocol producing the amides in 47-98% yield has been developed in which the purification involved only extractions and in a few cases filtration through an ion-exchange resin. It was found that 5mg of starting material was enough to obtain reproducible results and excellent purities. Thus, the procedure is estimated to be transferable to fully automated systems. The synthesized compounds were evaluated for their UII receptor agonistic activities using a cell-based assay (R-SAT). The most active compounds were the 4-trifluoromethylcinnamic amides of 1-(4-chlorophenyl)-3-dimethylamino-propylamine and 1-(2-naphthyl)-3-dimethylamino-propylamine, both showed EC(50) values of 130 nM.
Subject(s)
Naphthalenes/chemical synthesis , Propylamines/chemical synthesis , Receptors, G-Protein-Coupled/agonists , Animals , Drug Design , Humans , Mice , Models, Molecular , Molecular Conformation , NIH 3T3 Cells , Naphthalenes/chemistry , Naphthalenes/pharmacology , Propylamines/chemistry , Propylamines/pharmacology , Structure-Activity RelationshipABSTRACT
Chemical genomics is a drug discovery strategy that relies heavily on high-throughput screening (HTS) and therefore benefits from functional assay platforms that allow HTS against all relevant genomic targets. Receptor Selection and Amplification Technology (R-SAT) is a cell-based, high-throughput functional assay where the receptor stimulus is translated into a measurable cellular response through an extensive signaling cascade occurring over several days. The large biological and chronological separation of stimulus from response provides numerous opportunities for enabling assays and increasing assay sensitivity. Here we review strategies for building homogeneous assay platforms across large gene families by redirecting and/or amplifying signal transduction pathways.
Subject(s)
Genomics , Signal Transduction , Animals , Humans , Receptors, G-Protein-Coupled/metabolismABSTRACT
Six different series of nonpeptidic urotensin II receptor agonists have been synthesized and evaluated for their agonistic activity in a cell-based assay (R-SAT). The compounds are ring-opened analogues of the isochromanone-based agonist AC-7954 with different functionalities constituting the linker between the two aromatic ring moieties. Several of the compounds are highly potent and efficacious, with N-[1-(4-chlorophenyl)-3-(dimethylamino)-propyl]-4-phenylbenzamide oxalate (5d) being the most potent. The pure enantiomers of 5d were obtained from the corresponding diastereomeric amides. It was shown by a combination of X-ray crystallography and chemical correlation that the activity resides in the S-enantiomer of 5d (pEC(50) 7.49).
Subject(s)
Benzamides/chemical synthesis , Receptors, G-Protein-Coupled/agonists , Animals , Benzamides/chemistry , Benzamides/pharmacology , Crystallography, X-Ray , Esters/chemical synthesis , Esters/chemistry , Esters/pharmacology , Ethers/chemical synthesis , Ethers/chemistry , Ethers/pharmacology , Mice , Models, Molecular , Molecular Conformation , NIH 3T3 Cells , Receptors, G-Protein-Coupled/chemistry , Stereoisomerism , Structure-Activity Relationship , Sulfonamides/chemical synthesis , Sulfonamides/chemistry , Sulfonamides/pharmacology , Urea/analogs & derivatives , Urea/chemical synthesis , Urea/chemistry , Urea/pharmacologyABSTRACT
Drugs targeting retinoid receptors have been developed to treat a variety of therapeutic indications, but their success has been limited in part due to lack of selectivity. A novel functional cell-based assay R-SATtrade mark was employed to screen a small molecule chemical library and identify a variety of novel RAR agonists with various subtype selectivities, including RARbeta/gamma and RARgamma selective agonists. A novel class of synthetic compounds that distinguishes between the different RARbeta isoforms is described. This pharmacophore displays anti-proliferative activity and induces differentiation in a neuronal cell line, consistent with a classical retinoid mechanism of action while providing unique subtype selectivity. These novel subtype selective RAR agonists could serve as powerful tools to probe into subtype and isoform-specific retinoid function.
Subject(s)
Receptors, Retinoic Acid/agonists , Animals , Cell Line , Cell Proliferation , Humans , Mice , NeuritesABSTRACT
A functional cell-based screen identified 3-(4-chlorophenyl)-3-(2-(dimethylamino)ethyl)isochroman-1-one hydrochloride (AC-7954, 1) as a nonpeptidic agonist of the urotensin-II receptor. Racemic 1 had an EC50 of 300 nM at the human UII receptor and was highly selective. Testing of the enantiopure (+)- and (-)- 1 revealed that the UII receptor activity of racemic 1 resides primarily in (+)-1. Being a selective nonpeptidic druglike UII receptor agonist, (+)-1 will be useful as a pharmacological research tool and a potential drug lead.
Subject(s)
Chromans/chemistry , Receptors, Cell Surface/agonists , Receptors, G-Protein-Coupled , Animals , Chromans/pharmacology , Combinatorial Chemistry Techniques , Humans , Mice , Rats , Stereoisomerism , Structure-Activity RelationshipABSTRACT
Many naturally occurring peptides exhibit a high degree of promiscuity across G-protein coupled receptor subtypes. The degree to which this phenomenon occurs, and its physiological significance is not well characterized. In addition, many 'orphan' peptides exist for which there are no known receptors. Therefore, to identify novel interactions between biologically active peptides and G-protein coupled receptors, a library of nearly 200 peptides was screened against the human calcitonin (hCTr), human Parathyroid Hormone (PTH1R), human Corticotropin Releasing Factor (CRF1), and the human Glucagon-like peptide (GLP1) receptors using a cell-based functional assay (Receptor Selection and Amplification Technology). Functional profiling revealed that the 'orphan peptide' PHM-27 selectively activated the hCTr; no activity was observed at the PTH1, CRF1, or GLP1 receptors. PHM-27 was a potent agonist at the hCTr, with similar efficacy as human calcitonin, and a potency of 11 nM. These results were confirmed in cyclic AMP assays. Responses to calcitonin and PHM-27 could be suppressed by the antagonist salmon calcitonin (8-32). In competition binding studies, salmon calcitonin (8-32), calcitonin, and PHM-27 were each able to inhibit (125)I-calcitonin from cell membranes containing transiently expressed hCTr. These results indicate that the orphan peptide PHM-27 is a potent agonist at the hCTr.
Subject(s)
Peptide PHI/pharmacology , Receptors, Calcitonin/agonists , 3T3 Cells , Amino Acid Sequence , Animals , Binding, Competitive , Cells, Cultured , Cyclic AMP/metabolism , Humans , Mice , Molecular Sequence Data , Receptors, Calcitonin/metabolismABSTRACT
In this study, we investigated the cytotoxic effects of a broad-spectrum histone deacetylase (HDAC) inhibitor, PCI-24781, alone and in combination with the proteasome inhibitor bortezomib in neuroblastoma cell lines. The combination was shown to induce synergistic cytotoxity involving the formation of reactive oxygen species. The cleavage of caspase-3 and PARP, as determined by western blotting, indicated that cell death was primarily due to apoptosis. Xenograft mouse models indicated increased survival among animals treated with this combination. The Notch signaling pathway and MYCN gene expression were quantified by reverse transcription-polymerase chain reaction (PCR) in cells treated with PCI-24781 and bortezomib, alone and in combination. Notch pathway expression increased in response to an HDAC inhibitor. NFKB1 and MYCN were both significantly down regulated. Our results suggest that PCI-24781 and bortezomib are synergistic in neuroblastoma cell lines and may be a new therapeutic strategy for this disease.
ABSTRACT
Patients diagnosed with high-risk neuroblastoma (NB), an extracranial solid tumor in children, have metastases and low survival (30%) despite aggressive multi-modal therapy. Therefore new therapies are urgently needed. We show significant in vitro and in vivo antitumor efficacy of RKS262 in NB. RKS262 showed superior cytotoxicity (IC(50) = 6-25 µM) against six representative NB cell lines compared to its parent analog Nifurtimox (currently in phase 2). Pre-formulated RKS262 (150 mg/kg/daily) pellets administered orally, suppressed tumor growth (60%, p = 0.021) in NB xenograft mice within 28 days. RKS262-treated SMSKCNR cells showed TUNEL-positive DNA nicks and activation of ROS, MAPKs (SAPK/JNK), caspase-3, and p53, along with suppression of the IGF-1R/PI3K/PKC pathway and the Bcl2 family of proteins. RKS262 caused G(2)/M-phase arrest and suppressed cdc-2, cyclin B1, p21, and cyclin D1/D4 expression. N-acetyl-cysteine (NAC; 10 mM) pre-treatment rescued cell viability of RKS262 (23 µM)-treated SMSKCNR cells, and pre-treatment with ascorbic acid (100 µM) and a MAPK inhibitor SB203580 (20 µM) reversed SAPK/JNK, caspase-3 activation, PARP-1 cleavage, and suppression of IGF-1R, PI3K, and PKC phosphorylation. Further, treatment with exogenous BDNF (50 nM) did not suppress SAPK/JNK or ROS activation due to RKS262. Rather, BDNF (50 nM), EGF (100 nM) and IGF-1 (100 nM) co-treatment with RKS262 induced a remarkable S-phase arrest rather than a G(2)/M phase arrest when RKS262 was used alone. In summary, RKS262 shows oral efficacy in NB xenograft animals, and induces apoptosis in vitro in SMSKCNR cells via cell cycle arrest, MAPK and ROS activation, and suppression of IGF-1R/PI3K/PKC and Bcl2 family proteins in a growth factor (BDNF/EGF/IGF-1)-independent fashion.
Subject(s)
Antineoplastic Agents/pharmacology , Coumarins/pharmacology , Cyclic S-Oxides/pharmacology , JNK Mitogen-Activated Protein Kinases/metabolism , Neuroblastoma/metabolism , Neuroblastoma/pathology , Reactive Oxygen Species/metabolism , Tumor Burden/drug effects , Administration, Oral , Animals , Antineoplastic Agents/chemistry , Apoptosis/drug effects , Brain-Derived Neurotrophic Factor/pharmacology , Caspase 3/metabolism , Cell Cycle/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Coumarins/administration & dosage , Coumarins/chemistry , Cyclic S-Oxides/administration & dosage , Cyclic S-Oxides/chemistry , Epidermal Growth Factor/pharmacology , Female , Humans , Insulin-Like Growth Factor I/pharmacology , Mice , Mice, Nude , Proto-Oncogene Proteins c-bcl-2/metabolism , Xenograft Model Antitumor AssaysABSTRACT
A novel class of CB1 inverse agonists was discovered. To efficiently establish structure-activity relationships (SARs), new synthetic methodologies amenable for parallel synthesis were developed. The compounds were evaluated in a mammalian cell-based functional assay and in radioligand binding assays expressing recombinant human cannabinoid receptors (CB1 and CB2). In general, all of the compounds exhibited high binding selectivity at CB1 vs CB2 and the general SAR revealed a lead compound 11-(4-chlorophenyl)dibenzo[b,f][1,4]thiazepine-8-carboxylic acid butylamide (12e) which showed excellent in vivo activity in pharmacodynamic models related to CB1 receptor activity. The low solubility that hampered the development of 12e was solved leading to a potential preclinical candidate 11-(3-chloro-4-fluorophenyl)dibenzo[b,f][1,4]thiazepine-8-carboxylic acid butylamide (12h).
Subject(s)
Dibenzothiazepines/chemical synthesis , Receptor, Cannabinoid, CB1/antagonists & inhibitors , Thiazepines/chemical synthesis , Animals , Anti-Obesity Agents/chemical synthesis , Anti-Obesity Agents/chemistry , Anti-Obesity Agents/pharmacology , Appetite Depressants/chemical synthesis , Appetite Depressants/chemistry , Appetite Depressants/pharmacology , Cell Line , Combinatorial Chemistry Techniques , Dibenzothiazepines/chemistry , Dibenzothiazepines/pharmacology , Drug Inverse Agonism , Eating/drug effects , Humans , Hypothermia/chemically induced , In Vitro Techniques , Male , Mice , Mice, Inbred C57BL , Microsomes, Liver/metabolism , Models, Molecular , Radioligand Assay , Rats , Rats, Sprague-Dawley , Receptor, Cannabinoid, CB1/agonists , Solubility , Structure-Activity Relationship , Thiazepines/chemistry , Thiazepines/pharmacologyABSTRACT
Proteinase activated receptor-2 plays a crucial role in a wide variety of conditions with a strong inflammatory component. We present the discovery and characterization of two structurally different, potent, selective, and metabolically stable small-molecule PAR-2 agonists. These ligands may be useful as pharmacological tools for elucidating the complex physiological role of the PAR-2 receptors as well as for the development of PAR-2 antagonists.
Subject(s)
Receptor, PAR-2/agonists , Drug Design , Humans , Structure-Activity RelationshipABSTRACT
Peptides with agonist activity at the vasopressin V(2) receptor are used clinically to treat fluid homeostasis disorders such as polyuria and central diabetes insipidus. Of these peptides, the most commonly used is desmopressin, which displays poor bioavailability as well as potent activity at the V(1b) receptor, with possible stress-related adverse effects. Thus, there is a strong need for the development of small molecule chemistries with selective V(2) receptor agonist activity. Using the functional cell-based assay Receptor Selection and Amplification Technology (R-SAT((R))), a screening effort identified three small molecule chemotypes (AC-94544, AC-88324, and AC-110484) with selective agonist activity at the V(2) receptor. One of these compounds, AC-94544, displayed over 180-fold selectivity at the V(2) receptor compared to related vasopressin and oxytocin receptors and no activity at 28 other G protein-coupled receptors (GPCRs). All three compounds also showed partial agonist activity at the V(2) receptor in a cAMP accumulation assay. In addition, in a rat model of central diabetes insipidus, AC-94544 was able to significantly reduce urine output in a dose-dependent manner. Thus, AC-94544, AC-88324, and AC-110484 represent novel opportunities for the treatment of disorders associated with V(2) receptor agonist deficiency.
Subject(s)
Pharmaceutical Preparations/chemical synthesis , Pharmaceutical Preparations/metabolism , Receptors, Vasopressin/agonists , Receptors, Vasopressin/metabolism , Animals , Antidiuretic Agents/administration & dosage , Antidiuretic Agents/chemical synthesis , Deamino Arginine Vasopressin/administration & dosage , Deamino Arginine Vasopressin/chemistry , Deamino Arginine Vasopressin/metabolism , Deamino Arginine Vasopressin/therapeutic use , Diabetes Insipidus/prevention & control , Diabetes Insipidus/urine , Dose-Response Relationship, Drug , Humans , Male , Mice , NIH 3T3 Cells , Peptides/chemistry , Peptides/metabolism , Peptides/pharmacology , Peptides/therapeutic use , Pharmaceutical Preparations/administration & dosage , Rats , Rats, Brattleboro , Vasopressins/deficiency , Vasopressins/genetics , Vasopressins/metabolism , Vasopressins/therapeutic useABSTRACT
Using a high-throughput functional screen, the atypical L-type Ca2+ channel blocker diltiazem was discovered to be an agonist at the human ghrelin (GHSR1a) receptor. In cellular proliferation, Ca2+ mobilization, and bioluminescence resonance energy transfer (BRET-2) assays, diltiazem was a partial agonist at GHSR1a receptors, with 50 to 80% relative efficacy compared with the GHSR1a peptide agonist GHRP-6, and high nanomolar to low micromolar potency, depending upon the assay. Seven of the known primary metabolites of diltiazem were synthesized, and three of them (MA, M1, and M2) were more efficacious and/or more potent than diltiazem at GHSR1a receptors, with a rank order of agonist activity of M2 > M1 > MA > diltiazem, whereas M4 and M6 metabolites displayed weak agonist activity, and the M8 and M9 metabolites were inactive. Binding affinities of diltiazem and these metabolites to GHSR1a receptors followed a similar rank order. In vivo tests showed that diltiazem and M2 each stimulated growth hormone release in male Sprague-Dawley neonatal rats, although to a lesser degree than GHRP-6. Thus, diltiazem and chemical analogs of diltiazem represent a new class of GHSR1a receptor agonists. The possible contributions of GHSR1a receptor activation to the clinical actions of diltiazem are discussed in the context of the known beneficial cardiovascular effects of ghrelin.
Subject(s)
Calcium Channels, L-Type/drug effects , Diltiazem/pharmacology , Receptors, G-Protein-Coupled/agonists , Animals , Calcium/metabolism , Diltiazem/metabolism , Growth Hormone/metabolism , Humans , Luminescent Measurements , Male , Mice , NIH 3T3 Cells , Oligopeptides/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, GhrelinABSTRACT
A series of analogues of the selective non-peptide urotensin II (UII) receptor agonist 3-(4-chlorophenyl)-3-(2-dimethylaminoethyl)-isochroman-1-one (AC-7954, 1) was synthesized and evaluated for UII agonist activity using a functional cell-based assay. The introduction of a methyl group in the 4-position resulted in a complete loss of activity, whereas substituents in the aromatic rings were beneficial. Sterically demanding amino groups were also detrimental to the activity. Several potent agonists were identified, six compounds being equally or more potent than 1. The most potent compound in the series was the 6,7-dimethyl analogue of 1 (16, pEC50 6.87). The racemate of 16 was resolved into the pure enantiomers using preparative straight phase HPLC. It was shown that the potency resides in the (+)-enantiomer (pEC50 7.11). The synthesized compounds seem to be selective for the UII receptor as no activities were observed at the closely related SSTR3 and 5 receptors.
Subject(s)
Chromans/chemical synthesis , Chromans/pharmacology , Receptors, G-Protein-Coupled/agonists , 3T3 Cells , Animals , Chromans/chemistry , Humans , Mice , Models, Molecular , Molecular Structure , Receptors, G-Protein-Coupled/genetics , Stereoisomerism , Structure-Activity Relationship , TransfectionABSTRACT
Receptors have well-conserved regions that are recognized and activated by hormones and neurotransmitters. Most drugs bind to these sites and mimic or block the action of the native ligands. Using a high-throughput functional screen, we identified a potent and selective M(1) muscarinic receptor agonist from a novel structural class. Using a series of chimeric receptors, we demonstrated that this ligand activates the receptor through a region that is not conserved among receptor subtypes, explaining its unprecedented selectivity. This region of the receptor is distinct from the conserved region that is recognized by traditional ligands. The finding that receptors for small-molecule transmitters can have multiple, structurally distinct activation sites has broad implications for the study of receptor structure/function and the potential for the discovery of novel ligands with high selectivity.